Amanda Gross
Amanda Gross has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra McCraw
Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London, United Kingdom
20 shared publications - Alicia M. Chenoweth
King’s College London
20 shared publications - Amanda Clarke
SeromYx Systems, Inc., Woburn, Massachusetts
20 shared publications - Andrew N. J. Tutt
The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
20 shared publications - Anita Grigoriadis
The Breast Cancer Now Research Unit, King’s College London, London, UK
20 shared publications - Anna M. Davies
Randall Centre for Cell and Molecular Biophysics, King’s College London, New Hunt’s House
20 shared publications
Latest Publications
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 6: Binding of antibody variants to FcRn at pH 7.4 and pH 6.0. Recombinant human HER2 or FRα was coupled to microbeads and incubated with antibody variants for 2 hours, before being stained with PE-labelled tetramerized recombinant FcRn at either pH 7.4 or pH 6.0 and analyzed by flow cytometry. Data is n = 2-4, mean ± SEM.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 6: Binding of antibody variants to FcRn at pH 7.4 and pH 6.0. Recombinant human HER2 or FRα was coupled to microbeads and incubated with antibody variants for 2 hours, before being stained with PE-labelled tetramerized recombinant FcRn at either pH 7.4 or pH 6.0 and analyzed by flow cytometry. Data is n = 2-4, mean ± SEM.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 7: ADCC measured by flow cytometric analysis using Zombie Green Fixable Viability dye in a 4-hour co-culture of target cells and purified NK cells (1:3 ratio) in the presence of engineered antibodies (0.1 ng/mL). Bars represent n = 2 independent experiments with two different human NK cell donors, % specific lysis ± SEM.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 7: ADCC measured by flow cytometric analysis using Zombie Green Fixable Viability dye in a 4-hour co-culture of target cells and purified NK cells (1:3 ratio) in the presence of engineered antibodies (0.1 ng/mL). Bars represent n = 2 independent experiments with two different human NK cell donors, % specific lysis ± SEM.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Transcriptomic analysis of FCGR and immune cell expression in patients before and after chemotherapy and immunotherapy treatment. A, Uniform Manifold Approximation and Projection (UMAP) visualization of tumor-infiltrating lymphocytes in matched tumor samples taken before and after chemotherapy (GSE169246). B, Comparison of total immune cell counts of patients before and after chemotherapy treatment (GSE169246). C, Normalized log2 expression of FCGR1A, FCGR2A, FCGR2B, and FCGR3A (GSE169246). D, NanoString FcγR gene expression from two TNBC cohorts: Royal Marsden Hospital (RMH) and Guy’s and St Thomas’ NHS Trust (KCL). E and F, Proportion of FCGR3A-positive T cells and NK cells (E) and myeloid cells (F) determined by scRNA-seq analysis in TNBC patients before and during anti–PD-1 therapy. G, Representative spatial transcriptomic analysis from the publicly available dataset GSE210616. H and I, Spatial transcriptomic analyses of FOLR1 and FCGR expression (H) and colocalization frequency of FCGR genes with FOLR1 (I) before treatment (n = 12) and after treatment (n = 9). Statistical significance was determined using two-way ANOVA. ns, not significant.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Transcriptomic analysis of FCGR and immune cell expression in patients before and after chemotherapy and immunotherapy treatment. A, Uniform Manifold Approximation and Projection (UMAP) visualization of tumor-infiltrating lymphocytes in matched tumor samples taken before and after chemotherapy (GSE169246). B, Comparison of total immune cell counts of patients before and after chemotherapy treatment (GSE169246). C, Normalized log2 expression of FCGR1A, FCGR2A, FCGR2B, and FCGR3A (GSE169246). D, NanoString FcγR gene expression from two TNBC cohorts: Royal Marsden Hospital (RMH) and Guy’s and St Thomas’ NHS Trust (KCL). E and F, Proportion of FCGR3A-positive T cells and NK cells (E) and myeloid cells (F) determined by scRNA-seq analysis in TNBC patients before and during anti–PD-1 therapy. G, Representative spatial transcriptomic analysis from the publicly available dataset GSE210616. H and I, Spatial transcriptomic analyses of FOLR1 and FCGR expression (H) and colocalization frequency of FCGR genes with FOLR1 (I) before treatment (n = 12) and after treatment (n = 9). Statistical significance was determined using two-way ANOVA. ns, not significant.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Cell binding and Fab-mediated functionality of FcγRIIIa-enhanced antibodies. A, Binding of anti-HER2 and anti-FRα IgG variants (0.03–10 µg/mL) to NK cells evaluated by flow cytometry (n = 4). B and C, Binding of monomeric anti-HER2 IgG variants (0.0001–10 µg/mL) to HER2-expressing (SKBR3 and HCC1954) or nonexpressing (CAL51) cells (n = 3–6; B) or to FRα-expressing (CAL51 and T47D) or nonexpressing (SKBR3) cells (n = 3–6; C). D, Impact of antibodies on proliferation detected by live-cell imaging (Incucyte; n = 3). Representative images of cells treated with 10 μg/mL anti-HER2 antibody variants for 5 days. Scale bar, 100 μm. MFI, median fluorescence intensity.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Cell binding and Fab-mediated functionality of FcγRIIIa-enhanced antibodies. A, Binding of anti-HER2 and anti-FRα IgG variants (0.03–10 µg/mL) to NK cells evaluated by flow cytometry (n = 4). B and C, Binding of monomeric anti-HER2 IgG variants (0.0001–10 µg/mL) to HER2-expressing (SKBR3 and HCC1954) or nonexpressing (CAL51) cells (n = 3–6; B) or to FRα-expressing (CAL51 and T47D) or nonexpressing (SKBR3) cells (n = 3–6; C). D, Impact of antibodies on proliferation detected by live-cell imaging (Incucyte; n = 3). Representative images of cells treated with 10 μg/mL anti-HER2 antibody variants for 5 days. Scale bar, 100 μm. MFI, median fluorescence intensity.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 3: Non-reduced and reduced SDS-PAGE gels of antibody variants demonstrating structural integrity.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Figure 3: Non-reduced and reduced SDS-PAGE gels of antibody variants demonstrating structural integrity.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Table 2: PIPE PCR primers and cycling conditions.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Table 2: PIPE PCR primers and cycling conditions.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Table 1: Patient characteristics of bioinformatics analyses
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Table 1: Patient characteristics of bioinformatics analyses
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Table 3: Antibody variant production yield from transient transfection of 30mL Expi293F cells.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Supplementary Table 3: Antibody variant production yield from transient transfection of 30mL Expi293F cells.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Transcriptomic analysis of FcγR and immune cell expression. A and B, Uniform Manifold Approximation and Projection (UMAP) visualization of tumor-infiltrating lymphocytes from pretreatment samples, HER2+ (A) and TNBC (GSE176078; B). C and D,FCGR genes were plotted for each immune cell subtype for HER2+ (C) and TNBC (D). E, Comparison of normalized log2FCGR expression from bulk mRNA data from HER2+ patients before trastuzumab treatment (GSE76360). Patients were classified into pCR or no pCR. Statistical significance was calculated using the Wilcoxon test. F,FCGR3A expression and immune cell subtypes estimated using ConsensusTME from bulk mRNA data from HER2+ patients before trastuzumab treatment (GSE109710). G, Representative images of pretreatment TNBC, evaluated by spatial transcriptomic analysis of the publicly available dataset GSE210616 (24 tumor sections from 12 patients). H, Venn diagrams of coexpression of FOLR1 and FCGR from spatial transcriptomic analysis. *, P < 0.05; **, P < 0.01; ns, not significant.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
Transcriptomic analysis of FcγR and immune cell expression. A and B, Uniform Manifold Approximation and Projection (UMAP) visualization of tumor-infiltrating lymphocytes from pretreatment samples, HER2+ (A) and TNBC (GSE176078; B). C and D,FCGR genes were plotted for each immune cell subtype for HER2+ (C) and TNBC (D). E, Comparison of normalized log2FCGR expression from bulk mRNA data from HER2+ patients before trastuzumab treatment (GSE76360). Patients were classified into pCR or no pCR. Statistical significance was calculated using the Wilcoxon test. F,FCGR3A expression and immune cell subtypes estimated using ConsensusTME from bulk mRNA data from HER2+ patients before trastuzumab treatment (GSE109710). G, Representative images of pretreatment TNBC, evaluated by spatial transcriptomic analysis of the publicly available dataset GSE210616 (24 tumor sections from 12 patients). H, Venn diagrams of coexpression of FOLR1 and FCGR from spatial transcriptomic analysis. *, P < 0.05; **, P < 0.01; ns, not significant.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
FcγRIIIa-enhanced antibodies engender NK cell activation above IgG1-WT. A, CD69 and CD107a expression on NK cells measured by flow cytometry following cross-linking of FcγRIIIa by engineered antibodies (20 μg/mL) and anti-F(ab′)2 cross-linker (10 μg/mL; n = 3–4). Statistical significance was determined using one-way ANOVA. B, Intracellular calcium flux of purified human NK cells after cross-linking antibody variants with an anti-IgG. Ionomycin was used as a positive control. C, ADCC measured by LDH release in a 4-hour coculture of target cells (SKBR3, HCC1954, JIMT-1, CAL51) and purified NK cells (1:10) in the presence of antibodies (0.000001-10 μg/mL; n = 7–12). D, TNFα and IFNγ release measured by ELISA from a 6-hour coculture of target cells and purified NK cells (1:10) in the presence of antibodies (0.000001-10 μg/mL; n = 5). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
FcγRIIIa-enhanced antibodies engender NK cell activation above IgG1-WT. A, CD69 and CD107a expression on NK cells measured by flow cytometry following cross-linking of FcγRIIIa by engineered antibodies (20 μg/mL) and anti-F(ab′)2 cross-linker (10 μg/mL; n = 3–4). Statistical significance was determined using one-way ANOVA. B, Intracellular calcium flux of purified human NK cells after cross-linking antibody variants with an anti-IgG. Ionomycin was used as a positive control. C, ADCC measured by LDH release in a 4-hour coculture of target cells (SKBR3, HCC1954, JIMT-1, CAL51) and purified NK cells (1:10) in the presence of antibodies (0.000001-10 μg/mL; n = 7–12). D, TNFα and IFNγ release measured by ELISA from a 6-hour coculture of target cells and purified NK cells (1:10) in the presence of antibodies (0.000001-10 μg/mL; n = 5). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.